ROCO
6662
Market cap22mUSD
Oct 06, Last price
28.50TWD
1D
-0.35%
1Q
-4.04%
IPO
-56.42%
Name
BioLASCO Taiwan Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioLASCO Taiwan Co., Ltd., established in Taipei in 1990, operates as an international supplier of bio-materials and surgical support services. The company specializes in breeding and producing Specific Pathogen-Free (SPF) laboratory rodents, encompassing various outbreed stocks, inbreed strains, and immune-deficient models, alongside providing bespoke animal model services. Its product portfolio extends to critical diagnostic and research tools, including kits for endotoxin detection, animal health diagnostics, and serological analysis, as well as biological indicators. Furthermore, BioLASCO furnishes a comprehensive array of laboratory equipment vital for animal research and facility management. This sophisticated equipment includes Individually Ventilated Cage (IVC) systems and ventilated housing units, professional automated animal watering systems, transponders, chlorine dioxide gas generators, and specialized devices such as mouse and rat tail cuff blood pressure systems, analgesia equipment, animal behavioral systems, metabolism and behavior tracking systems. The company also offers XPERT cabinet X-ray systems, automatic cleaning equipment, laboratory workstations, isolation chambers, and foggers.
Key people
Zhenzhong Chen
Chairman of the Board · since 2021
Yonghao Chen
General Manager · since 2021
Ningyuan Cai
Deputy General Manager-Biotechnology Division · since 2016
Beck Chang
Head of Finance & Accounting · since 2025
Junwei Chen
Director · since 2017
Weiming Liu
Director · since 2008
Independent Director · since 2018
Chin Ting Wang
Independent Director · since 2025
Fengji Zheng
Independent Director · since 2023
Hanxin Zheng
Independent Director · since 2018
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT |